These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 31733288)

  • 1. Dysregulation of de novo nucleotide biosynthetic pathway enzymes in cancer and targeting opportunities.
    Robinson AD; Eich ML; Varambally S
    Cancer Lett; 2020 Feb; 470():134-140. PubMed ID: 31733288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical pharmacology of anticancer agents [Part 5] Antimetabolites (2)].
    Nakamura T; Ueda T; Uchida M
    Gan To Kagaku Ryoho; 1992 Mar; 19(3):409-20. PubMed ID: 1543370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis.
    Mendelsohn LG; Shih C; Chen VJ; Habeck LL; Gates SB; Shackelford KA
    Semin Oncol; 1999 Apr; 26(2 Suppl 6):42-7. PubMed ID: 10598554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of antimetabolites of purine and pyrimidine nucleotide metabolism in tumor cell differentiation.
    Hatse S; De Clercq E; Balzarini J
    Biochem Pharmacol; 1999 Aug; 58(4):539-55. PubMed ID: 10413291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA).
    Shih C; Habeck LL; Mendelsohn LG; Chen VJ; Schultz RM
    Adv Enzyme Regul; 1998; 38():135-52. PubMed ID: 9762351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticancer antifolates: current status and future directions.
    McGuire JJ
    Curr Pharm Des; 2003; 9(31):2593-613. PubMed ID: 14529544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Folate and antifolate pharmacology.
    Kamen B
    Semin Oncol; 1997 Oct; 24(5 Suppl 18):S18-30-S18-39. PubMed ID: 9420019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence for a localized conversion of endogenous tetrahydrofolate cofactors to dihydrofolate as an important element in antifolate action in murine leukemia cells.
    Matherly LH; Muench SP
    Biochem Pharmacol; 1990 Jun; 39(12):2005-14. PubMed ID: 2141258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitors of de novo nucleotide biosynthesis as drugs.
    Christopherson RI; Lyons SD; Wilson PK
    Acc Chem Res; 2002 Nov; 35(11):961-71. PubMed ID: 12437321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New mechanisms for an old drug; DHFR- and non-DHFR-mediated effects of methotrexate in cancer cells.
    Neradil J; Pavlasova G; Veselska R
    Klin Onkol; 2012; 25 Suppl 2():2S87-92. PubMed ID: 23581023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histidine catabolism is a major determinant of methotrexate sensitivity.
    Kanarek N; Keys HR; Cantor JR; Lewis CA; Chan SH; Kunchok T; Abu-Remaileh M; Freinkman E; Schweitzer LD; Sabatini DM
    Nature; 2018 Jul; 559(7715):632-636. PubMed ID: 29995852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes.
    Shih C; Chen VJ; Gossett LS; Gates SB; MacKellar WC; Habeck LL; Shackelford KA; Mendelsohn LG; Soose DJ; Patel VF; Andis SL; Bewley JR; Rayl EA; Moroson BA; Beardsley GP; Kohler W; Ratnam M; Schultz RM
    Cancer Res; 1997 Mar; 57(6):1116-23. PubMed ID: 9067281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of HL-60 leukemia cell differentiation by tetrahydrofolate inhibitors of de novo purine nucleotide biosynthesis.
    Sokoloski JA; Beardsley GP; Sartorelli AC
    Cancer Chemother Pharmacol; 1991; 28(1):39-44. PubMed ID: 2040032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitochondrial purine and pyrimidine metabolism and beyond.
    Wang L
    Nucleosides Nucleotides Nucleic Acids; 2016 Dec; 35(10-12):578-594. PubMed ID: 27906631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of methotrexate on nucleotide pools in normal human T cells and the CEM T cell line.
    Budzik GP; Colletti LM; Faltynek CR
    Life Sci; 2000; 66(23):2297-307. PubMed ID: 10855951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells.
    Chen VJ; Bewley JR; Andis SL; Schultz RM; Iversen PW; Shih C; Mendelsohn LG; Seitz DE; Tonkinson JL
    Br J Cancer; 1998; 78 Suppl 3(Suppl 3):27-34. PubMed ID: 9717988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Folylpoly-γ-glutamate synthetase: A key determinant of folate homeostasis and antifolate resistance in cancer.
    Raz S; Stark M; Assaraf YG
    Drug Resist Updat; 2016 Sep; 28():43-64. PubMed ID: 27620954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of HL-60 leukemia cell differentiation by the novel antifolate 5,10-dideazatetrahydrofolic acid.
    Sokoloski JA; Beardsley GP; Sartorelli AC
    Cancer Res; 1989 Sep; 49(17):4824-8. PubMed ID: 2758415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methotrexate and Pralatrexate.
    Wood GS; Wu J
    Dermatol Clin; 2015 Oct; 33(4):747-55. PubMed ID: 26433846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Computer modelling of antifolate inhibition of folate metabolism using hybrid functional petri nets.
    Assaraf YG; Ifergan I; Kadry WN; Pinter RY
    J Theor Biol; 2006 Jun; 240(4):637-47. PubMed ID: 16352313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.